nivolumab,ipilimumab
ono Pharmaceuticals,bms
['nivo', 'nivolumab', 'ipilimumab', 'tnbc', 'bellini']
at #esmo22 presented results from #bellini trial: 4 weeks of nivolumab + ipilimumab in early tnbc with tils (&gt;5%) in the preoperative setting induce immune response in early tumors 
MD, Medical Oncologist????•Research Fellow at @JulesBordet Institute in Brussels???? Great interest in #BreastCancer and #ImmunoOncology